Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Células Neoplásicas Circulantes/efectos de los fármacos , Anticuerpos Monoclonales Humanizados , Neoplasias de la Mama/genética , Neoplasias de la Mama/mortalidad , Femenino , Humanos , Estimación de Kaplan-Meier , Terapia Neoadyuvante , Receptor ErbB-2/genética , Receptor ErbB-2/metabolismo , Trastuzumab , Resultado del TratamientoRESUMEN
BACKGROUND: Having demonstrated in a previous report that the response of circulating epithelial tumor cells (CETC) during the first cycles of primary (neoadjuvant) chemotherapy perfectly reflects the response of the tumor, in the present study the changes in cell numbers during subsequent cycles and their possible impact on the therapy's outcome were examined. PATIENTS AND METHODS: In 58 breast cancer patients CETC were quantified during therapy with either EC (epirubicin/ cyclophosphamid) or dose intensified E (epirubicin) followed by taxane, with or without trastuzumab, and subsequent CMF (cyclophosphamid/methorexate/ fluorouracil). RESULTS: CETC numbers declined more than 10-fold (good response) in 65% (her2/neu-negative) and 55% (her2/neu-positive) of patients during EC, and in 60% during dose intensified E, respectively, followed by an increase of CETC in all patients. CETC remained increased, decreasing only when adding CMF. A good initial response correlated with estrogen-receptor negativity, a poor response with early distant relapse (P < 0,0001, hazard ratio = 11.91). CONCLUSION: Response of CETC already during the first cycles of neoadjuvant treatment predicts the final response of the tumor. Hitherto unknown effects of the release of tumor cells during therapy further our understanding of tumor-blood interaction and may improve access of agents like antibodies to cells. The impact on the further course of disease remains to be evaluated.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/sangre , Neoplasias de la Mama/terapia , Células Epiteliales/patología , Células Neoplásicas Circulantes/patología , Neoplasias de la Mama/metabolismo , Femenino , Humanos , Terapia Neoadyuvante , Pronóstico , Receptor ErbB-2/metabolismo , Receptores de Estrógenos/metabolismo , Receptores de Progesterona , Resultado del TratamientoRESUMEN
In this study praevalence and stage of some selected symptoms within the orofacial complex were investigated in 600 normal children living in Jena (300 boys and 300 girls). The first problem of this study consisted in registering the biological variability of 6 symptoms (bit abnormality, protrusion of the lower lip, diastema, palatal height, size of the tongue, fissured tongue) in a normal group, and secondly to find correlations between these symptoms. The results are listed for the age groups according to sex. The supposed causes that may lead to the development of these symptoms are discussed. Our results were compared with those of the literature. Difficulties and incompletion are involved in recording of the mentioned symptoms and their value of diagnosis.